Experience

• • Due to the sensitive nature of Mr. Rubin’s confidential work counseling companies on FDA/FTC compliance matters, and handling non-public investigations, only a portion of his representative matters can be publicly disclosed.

• Mergers & Acquisitions –Regulatory Due Diligence

  • TPG Capital in the sale of Adare Pharmaceuticals, a leading specialty contract development and manufacturing organization, to Thomas H. Lee Partners and Frazier Healthcare Partners and the related separation of Adare’s Eosinophilic Esophagitis product into a TPG-backed entity.
  • Johnson & Johnson in its acquisition of TARIS, a biotechnology company specializing in the development of a novel drug delivery technology for the treatment of cancer.
  • Allergan in its sale of Brazikumab to AstraZeneca and Zenpep to Nestle.
  • Prudential Financial in its $2.35 billion acquisition of Assurance IQ, a direct-to-consumer platform that transforms the buying experience for individuals seeking personalized health and financial wellness solutions.
  • Manna Pro, a manufacturer and marketer of pet care and nutrition products and a Morgan Stanley Capital Partners portfolio company, in its acquisition of Hero Pet Brands.
  • CPPIB in its investment in a Series B fundraising in Sana Biotechnology, a U.S.-based biotech company focused on creating and delivering engineered cells as treatments for disease.

• FDA/FTC Compliance Matters

  • Numerous FDA and non-FDA regulated companies in confidential FTC investigations.
  • A leading marketing company in settling advertising allegations with the FTC.
  • Numerous pharmaceutical, medical device, and consumer product companies in addressing complex FDA compliance issues.
  • Numerous investment banks and financial services companies in various hemp and CBD regulatory issues.
  • Medical Device Innovation Consortium, in preparing a comprehensive “cybersecurity playbook” for the medical device industry.